Identification of cellular and molecular factors determining the response of cancer cells to six ergot alkaloids

Investigational New Drugs

Volumn 33, Issue 1, 2015, Pages 32-44

  Mrusek, Marco ^a   Seo, Ean Jeong ^a   Greten, Henry Johannes ^b,c   Simon, Michael ^a   Efferth, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF PORTO   (Portugal)

^c Heidelberg School of Chinese Medicine   (Germany)

Author keywords

Alkaloids; Cancer; Claviceps purpurea; Clavicipitaceae; Microarrays; Pharmacogenomics

Indexed keywords

1 PROPYLAGROCLAVINE TARTRATE; AGROCLAVINE; ALKYLATING AGENT; CISPLATIN; CYCLINE; DAUNORUBICIN; DIHYDROERGOCRISTINE; ERGOCORNINE E; ERGOSTEROL; ERGOT ALKALOID; ERGOTAMINE; ERLOTINIB; HORMONE ANTAGONIST; MULTIDRUG RESISTANCE PROTEIN; RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MESSENGER RNA;

ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE; CELL DIVISION; CELL PROLIFERATION; CLUSTER ANALYSIS; CONTROLLED STUDY; CROSS RESISTANCE; DRUG CYTOTOXICITY; DRUG RESPONSE; EGFR GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; IC50; MDR1 GENE; MICROARRAY ANALYSIS; ONCOGENE; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TP53 GENE; TUMOR SUPPRESSOR GENE; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ERGOT ALKALOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROARRAY ANALYSIS; NEOPLASMS; RNA, MESSENGER;

EID: 84922084106     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0168-4     Document Type: Article

References (58)

1. Hesseltine CW (1974) Natural Occurence of Mycotoxins in Cereals. Mycopathol Mycol Applic 53:141-153
2. Mulac D, Lepski S, Ebert F, Schwerdtle T, Humpf HU (2013) Cytotoxicity and Fluorescence Visualization of Ergot Alkaloids in Human Cell Lines. J Agricult Food Chem 61:462-471
3. Ayarragaray JE (2013) Ergotism: A Change of Persepective. Ann Vasc Surg 2013 [epub ahead of print]
4. Houghton PJ, Howes MJ (2005) Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease. Neurosignals 14:6-22
5. Tepper SJ (2013) Orally inhaled dihydroergotamine: a review. Headache 53(Suppl 2):43-53
6. Gizzo S, Patrelli TS, Gangi SD, Carrozzini M, Saccardi C, Zambon A, Bertocco A, Fagherazzi S, D'Antona D, Nardelli GB (2013) Which uterotonic is better to prevent the postpartum hemorrhage? Latest news in terms of clinical efficacy, side effects, and contraindications: a systematic review. Reprod Sci 20:1011-1019
7. Li SM, Unsöld IA (2006) Post-genome research on the biosynthesis of ergot alkaloids. Planta Med 72:1117-1120
8. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589-601
9. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR (1990) Comparison of in vitro anticancer-drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82:1113-1118
10. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236-244
11. Amundson SA, Do KT, Vinikoor LC, Lee RA, Koch-Paiz CA, Ahn J, Reimers M, Chen Y, Scudiero DA, Weinstein JN, Trent JM, Bittner ML, Meltzer PS, Fornace AJ Jr (2008) Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res 68:415-424
12. Efferth T, Fabry U, Osieka R (1997) Apoptosis and resistance to daunorubicin in human leukemic cells. Leukemia 11:1180-1186
13. Efferth T, Herrmann F, Tahrani A, Wink M (2011) Cytotoxic activity of secondary metabolites derived from Artemisia annua L. towards cancer cells in comparison to its designated active constituent artemisinin. Phytomedicine 18:959-969
14. Volm M, Koomägi R, Mattern J, Efferth T (2002) Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br J Cancer 87:251-257
15. Wosikowski K, Silverman JA, Bishop P, Mendelsohn J, Bates SE (2000) Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells. Biochim Biophys Acta 1497:215-226
16. Efferth T, Koch E (2011) Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr Drug Targets 12:122-132
17. Efferth T, Konkimalla VB, Wang YF, Sauerbrey A, Meinhardt S, Zintl F, Mattern J, Volm M (2008) Prediction of broad spectrum resistance of tumors towards anticancer drugs. Clin Cancer Res 14(8):2405-2412
18. El-Deiry WS (2003) The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22:7486-7495
19. Sklar MD (1988) The ras oncogenes increase the intrinsic resistance of NIH 3 T3 cells to ionizing radiation. Science 239:645-647
20. Sklar MD (1988b) Increased resistance to cis-diamminedichloroplatinum (II) in NIH 3 T3 cells transformed by ras oncogenes. Cancer Res48:793-797 Erratum in: Cancer Res 1988;48 (13):3889.
21. Eich E, Eichberg D, Clavines MWE (1984) New antibiotics with cytostatic activity. Biochem Pharmacol 33:523-526
22. Eich E, Becker C, Mayer K, Maidhof A, Müller WE (1986) Clavines as antitumor agents; 2. Natural 8-hydroxymethyl-ergoline type clavines and their derivatives. Planta Med 4:290-294
23. Faatz W, Pertz H, Maidhof A, Müller WEG, Eich E (1989) Antitumor compounds derived from the ergot minor alkaloid pyroclavine. Planta Med 55:653-654
24. Eich E, Pertz H (1999) antimicrobial and antitumor effects of ergot alkaloidfs and their derivatives. In: Kren V, Cvak L (eds.) Ergot. The genus claviceps. Harwood Academic Publishers
25. Efferth T, Olbrich A, Bauer R (2002) mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem Pharmacol 64:617-623
26. Sertel S, Eichhorn T, Bauer J, Hock K, Plinkert PK, Efferth T (2012) Pharmacogenomic determination of genes associated with sensitivity or resistance of tumor cells to curcumin and curcumin derivatives. J Nutr Biochem 23:875-884
27. Efferth T, Miyachi H, Bartsch H (2007) Pharmacogenomics of a traditional Japanese herbal medicine (Kampo) for cancer therapy. Cancer Genomics Proteomics 4:81-92
28. Wiench B, Chen YR, Paulsen M, Hamm R, Schröder S, Yang NS, Efferth T (2013) Integration of different "-omics" technologies identifies inhibition of the IGF1R-Akt-mTOR signaling cascade involved in the cytotoxic effect of shikonin against leukemia cells. Evid Based Complement Alternat Med 2013:818709
29. Thornier MO, Flückinger E, Calne DB (1980) Bromocriptine, a clinical and pharmacological review. Raven Press New, York
30. Glatt H, Eich E, Pertz H, Becker C, Oesch F (1987) Mutagenicity experiments on agroclavines, new natural antineoplastic compounds. Cancer Res 47:1811-1814
31. Glatt H, Pertz H, Kasper R, Eich E (1992) Clavine alkaloids and derivatives as mutagens detected in the Ames test. Anticancer Drugs 3:609-614
32. Efferth T (2001) The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr Mol Med 1:45-65
33. Gillet JP, Efferth T, Remacle J (2007) Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 1775:237-262
34. Gottesman MM, Ling V (2006) The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 580:998-1009
35. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG (2002) Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther 303:323-332
36. Orlowski S, Valente D, Garrigos M, Ezan E (1998) Bromocriptine modulates P-glycoprotein function. Biochem Biophys Res Commun 244:481-488
37. Goh AM, Coffill CR, Lane DP (2011) The role of mutant p53 in human cancer. J Pathol 223:116-126
38. Müller M, Schleithoff ES, Stremmel W, Melino G, Krammer PH, Schilling T (2006) One, two, three-p53, p63, p73 and chemosensitivity. Drug Resist Updat 9:288-306
39. Mulac D, Humpf HU (2011) Cytotoxicity and accumulation of ergot alkaloids in human primary cells. Toxicology 282:112-121
40. Mulac D, Lepski S, Ebert F, Schwerdtle T, Humpf HU (2013) Cytotoxicity and fluorescence visualization of ergot alkaloids in human cell lines. J Agric Food Chem 61:462-471
41. El-Deiry WS (1997) Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 9:79-87
42. Evans A, Bates V, Troy H, Hewitt S, Holbeck S, Chung YL, Phillips R, Stubbs M, Griffiths J, Airley R (2008) Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother Pharmacol 61:377-393
43. Fagan V, Bonham S, Carty MP, Saenz-Méndez P, Eriksson LA, Aldabbagh F (2012) COMPARE analysis of the toxicity of an iminoquinone derivative of the imidazo [5,4-f] benzimidazoles with NAD (P) H:quinone oxidoreductase 1 (NQO1) activity and computational docking of quinones as NQO1 substrates. Bioorg Med Chem 20:3223-3232
44. Luzina EL, Popov AV (2012) Synthesis, evaluation of anticancer activity and COMPARE analysis of N-bis (trifluoromethyl) alkyl-N'-substituted ureas with pharmacophoric moieties. Eur J Med Chem 53:364-373
45. Villeneuve DJ, Parissenti AM (2004) The use of DNA microarrays to investigate the pharmacogenomics of drug response in living systems. Curr Top Med Chem 4:1329-1345
46. Zeeberg BR, Liu H, Kahn AB, Ehler M, Rajapakse VN, Bonner RF, Brown JD, Brooks BP, Larionov VL, Reinhold W, Weinstein JN, Pommier YG (2011) RedundancyMiner: De-replication of redundant GO categories in microarray and proteomics analysis. BMC Bioinformatics 12:52
47. Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, Marshall R, Perry A, Bjorgan KM, Chaumeil MM, Ronen SM, Bergers G, Aghi MK (2013) Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res 19:1773-1783
48. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, Doroshow J, Pommier Y (2012) Cell Miner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res 72:3499-3511
49. Efferth T (2012) Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules. Curr Med Chem 19:5735-5744
50. Varlakhanova NV, Knoepfler PS (2009) Acting locally and globally: Myc's ever-expanding roles on chromatin. Cancer Res 69:7487-7490
51. Torigoe T, Izumi H, Ishiguchi H, Yoshida Y, Tanabe M, Yoshida T, Igarashi T, Niina I, Wakasugi T, Imaizumi T, Momii Y, Kuwano M, Kohno K (2005) Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 5:15-27
52. Lambert T (2012) Antibiotics that affect the ribosome. Rev Sci Tech 31:57-64
53. McCusker KP, Fujimori DG (2012) The chemistry of peptidyltransferase center-targeted antibiotics: enzymatic resistance and approaches to countering resistance. ACS Chem Biol 7:64-72
54. Keenan J, Murphy L, Henry M, Meleady P, Clynes M (2009) Proteomic analysis of multidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line. Proteomics 9:1556-1566
55. Larson BT, Samford MD, Camden JM, Piper EL, Kerley MS, Paterson JA, Turner JT (1995) Ergovaline binding and activation of D2 dopamine receptors in GH4ZR7 cells. J Anim Sci 73:1396-1400
56. Pertz H (1996) Naturally occurring clavines: antagonism/partial agonism at 5-HT2A receptors and antagonism at alpha 1-adrenoceptors in blood vessels. Planta Med 62:387-392
57. Eich E, Becker C, Sieben R, Maidhof A, Müller WE (1986) Clavines as antitumor agents, 3: Cytostatic activity and structure/activity relationships of 1-alkyl agroclavines and 6-alkyl 6-noragroclavines. J Antibiot 39:804-812
58. Eich E, Pertz H, Müller WEG (1987) Neuen Festuclavin- und Pyroclavin-derivate, Verfahren zu ihrer Herstellung und deren Verwendung als Arzneimittel. Offenlegungsschrift deutsches Patentamt DE 37 30 124 (16.09.1989)